Keywords: Ummutep, GlaxoSmithKline, License, Autoimmune diisease, ImmuTune

France’s Immutep signs deal worth up to $100 million with GlaxoSmithKline for ImmuTune IMP731

Article | 07 January 2011

Print This

Immutep SA of France has entered into a licence agreement granting UK pharma giant GlaxoSmithKline (LSE: GSK) exclusive worldwide rights ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in